Cassini, a pioneer in the development of corneal diagnostic solutions, announced today that it has closed a Series A financing round with venture capital fund Innovation Industries. The injection of capital will accelerate the development and successful commercialization of Cassini, a diagnostic platform for premium refractive cataract surgery procedures.
Twelve clinical studies on improving outcomes of cataract surgery with Cassini, a novel diagnostic platform based on multi-color LED technology, will be presented at the upcoming ESCRS meeting in Lisbon, Portugal from October 7-11, 2017. The studies cover a wide range of research interests, including measurement of the posterior cornea, femtosecond laser assisted arcuate incisions for treatment of astigmatism and comparative studies of Cassini and other diagnostic technologies.
Cassini announced the release of system improvements to its Cassini Corneal Shape Analyzer with the 2.5 version of software. Improvements to Cassini were based on close collaboration with leading eye surgeons and focused on further increasing precision and efficiency.
Cassini announced the release of system improvements to its Cassini Corneal Shape Analyzer with the 2.4.1 version of software. Improvements to Cassini were based on close collaboration with leading eye surgeons and focused on further increasing precision and efficiency.
Cassini has received the distinction to present at the Ophthalmology Futures Asian Forum which is held on March 1st 2017 in Singapore. The event connects scientists, entrepreneurs, physicians, regulators, corporate leaders and venture capitalists to drive innovation within the eye-care market.
Kentucky College of Optometry (KYCO) at the University of Pikeville has announced a collaboration with Cassini to provide the next generation of optometrists with the most innovative corneal analysis using the Cassini Corneal Shape Analyzer.
Mark Packer MD, Chief Medical Officer will highlight Cassini as core technology in today’s refractive cataract surgery ecosystem. Cassini enables seamless integration of clinic and operating suite, from preoperative diagnostics through visualization and laser applications to postoperative analysis. Cassini data demonstrate 94.0% reduction of astigmatism to target, 0.50 Diopter or less. These results help increase the adoption of premium cataract surgery and Advanced Technology IOL’s.